Open AccessAbstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models
Author(s) -
Larissa S. Carnevalli,
Danielle Carrol,
Michele Moschetta,
Pablo Morentin Gutierrez,
Cristina Gardelli,
Molly A. Taylor,
Antônio Marcos,
Adina Hughes,
M. King,
Teresa Klinowska,
Simon T. Barry
Publication year - 2019
Publication title -
tumor biology
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1423-0380
pISSN - 1010-4283
DOI - 10.1158/1538-7445.sabcs18-100
Subject(s) - blockade , refractory (planetary science) , immunotherapy , immune checkpoint , medicine , cancer research , pd l1 , discovery and development of mtor inhibitors , immune system , pi3k/akt/mtor pathway , immunology , biology , receptor , signal transduction , microbiology and biotechnology , astrobiology